 REDWOOD CITY, Calif., Feb. 22, 2021 GLOBE NEWSWIRE -- Adverum Biotechnologies, Inc. Nasdaq: ADVM, a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Reed V. Tuckson, M.D., FACP as an independent member of Adverums Board of Directors. Dr. Tuckson brings extensive policy knowledge from his experience in multiple facets of the healthcare industry, including a 13-year tenure in senior leadership positions at UnitedHealth Group, where he served as chief of medical affairs. 